Meeting
2023 ASCO Annual Meeting
Neoadjuvant camrelizumab plus chemotherapy for locally advanced cervical cancer (NACI study): A prospective, single-arm, phase II trial.
Authors
Jing Chen
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
Jing Chen , Kezhen Li , Yingjie Hu , Yingyan Han , Yuanming Shen , Yanzhou Wang , Kun Song , Bairong Xia , Xiaojun Chen , Dongling Zou , Yingmei Wang , Chaoyang Sun , Gang Chen , Ding Ma
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Cervical Cancer
Clinical Trial Registration Number
NCT04516616
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 5520)
DOI
10.1200/JCO.2023.41.16_suppl.5520
Abstract #
5520
Poster Bd #
214
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Efficacy and safety of camrelizumab combined with chemotherapy versus chemotherapy alone as preoperative neoadjuvant therapy for resectable locally advanced esophageal squamous cell carcinoma: Preliminary results from a multicenter, prospective, randomized controlled study.
First Author: Renquan Zhang
Poster
2023 ASCO Annual Meeting
Camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma (ESCC): A single-arm, phase II trial.
First Author: Lei Gong
Poster
2021 ASCO Annual Meeting
Camrelizumab plus chemotherapy as neoadjuvant therapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC-ESCC2019): A multicenter, open-label, single-arm, phase 2 study.
First Author: Jingpei Li
Poster
2024 ASCO Genitourinary Cancers Symposium
A phase II study of neoadjuvant tislelizumab and axitinib in patients with locally advanced non-metastatic clear cell renal cell carcinoma (accRCC).
First Author: Shun Zhang